Y.D. More Investments Ltd Sells 258,630 Shares of Sanofi (NASDAQ:SNY)

Y.D. More Investments Ltd trimmed its holdings in Sanofi (NASDAQ:SNY) by 95.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,710 shares of the company’s stock after selling 258,630 shares during the period. Y.D. More Investments Ltd’s holdings in Sanofi were worth $632,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Envestnet Asset Management Inc. lifted its position in shares of Sanofi by 29.8% in the third quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after buying an additional 651,756 shares in the last quarter. Natixis Advisors L.P. increased its stake in Sanofi by 15.9% during the third quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock worth $135,618,000 after acquiring an additional 346,563 shares during the last quarter. Morgan Stanley increased its stake in Sanofi by 4.6% during the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock worth $392,796,000 after acquiring an additional 323,968 shares during the last quarter. Clough Capital Partners L P bought a new position in shares of Sanofi during the third quarter valued at approximately $14,719,000. Finally, Soros Fund Management LLC bought a new position in Sanofi in the third quarter worth approximately $11,533,000. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. TheStreet lowered Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Finally, Morgan Stanley began coverage on Sanofi in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $55.00.

Sanofi Stock Performance

SNY stock traded up $0.80 during midday trading on Wednesday, reaching $50.03. The stock had a trading volume of 1,340,383 shares, compared to its average volume of 2,016,453. The stock has a market cap of $126.56 billion, a PE ratio of 24.71, a P/E/G ratio of 1.37 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.27. The firm has a fifty day simple moving average of $47.82 and a two-hundred day simple moving average of $48.25. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.93.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. As a group, equities research analysts anticipate that Sanofi will post 4.11 EPS for the current year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This is an increase from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio (DPR) is currently 73.87%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.